Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.
Official title: A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2026-09
Completion Date
2026-12
Last Updated
2026-09-04
Healthy Volunteers
No
Interventions
Tirzepatide
Administered SC.
Acetaminophen
Administered orally.
Placebo
Administered SC.
Locations (1)
Clinical Pharmacology of Miami
Miami, Florida, United States